1. Resources
  2. Blogs
  3. Clinical Care Plans

Blog: TherigySTM Atopic Dermatitis Therapeutic Category

With countless hours of research by our pharmacist's industry experts, we have developed best-in-class assessments to help track and monitor therapy medication regimen, side effects, patient-reported outcomes accurately in your specialty pharmacy setting. 

What is Atopic Dermatitis?

Atopic dermatitis (AD) is a common, chronic, inflammatory skin disease also known as eczema. AD is diagnosed based on the clinical presentation of eczematous lesions, dry skin, and the hallmark symptom of itching. 

atopic dermatitis

How many Americans are affected by Atopic Dermatitis?

Atopic Dermatitis (AD) is prevalent in up to 25% of children and 7% of the U.S. adult population. AD, directly and indirectly, costs the U.S. economy roughly $5 billion annually. The economic burden to an AD patient is significant, as they can spend up to $9,800 more in health care utilization than a non-AD patient per year.  There are many negative impacts on an AD patient's life, including reduced quality of life, sleep disruption, emotional distress, and impacts to work and social life.


How does TherigySTM's new module: Atopic Dermatitis enable clinicians to help manage and monitor AD patients?

In Therigy's Atopic Dermatitis module, evidence-based medicine is provided that will guide clinicians to help their patients achieve and maintain control of their AD. Such topics include:

  • Patient assessment questions about itch, sleep, impact on daily activity, and persistence of disease. 
  • Ratings of itch intensity, from head to toe.
  • Baseline assessments including itch severity, pain severity, and either the PROMIS Global-10 or the CDLQI or DLQI. The latter three quality of life assessments will dictate how the patient is tolerating their step-wise treatment plan and how the patient is dealing with his or her disease as a whole in day-to-day life.

The AD module also includes reports that can be generated to provide a clear picture of patients receiving treatment. Such reports include program performance and outcomes, as well as patient therapy compliance and outcomes.

To learn more about the Atopic Dermatitis module and the capabilities of TherigySTM, contact us for more information.